$940,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit. Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services and the Department of Veterans Affairs for physical conditions associated with mental illness, such as Tardive Dyskinesia."
You can find more data on corporate lobbying on Quiver Quantitative.
NBIX Insider Trading Activity
NBIX insiders have traded $NBIX stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $NBIX stock by insiders over the last 6 months:
- KYLE GANO (Chief Executive Officer) has made 0 purchases and 3 sales selling 36,700 shares for an estimated $4,873,049.
- WILLIAM H RASTETTER sold 18,000 shares for an estimated $2,732,689
- GARY A LYONS sold 15,000 shares for an estimated $2,289,082
- GEORGE J MORROW sold 15,000 shares for an estimated $2,150,512
- LESLIE V NORWALK has made 0 purchases and 2 sales selling 6,190 shares for an estimated $945,701.
- ERIC BENEVICH (Chief Commercial Officer) sold 5,970 shares for an estimated $905,880
- DARIN LIPPOLDT (Chief Legal Officer) sold 4,376 shares for an estimated $698,615
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NBIX Hedge Fund Activity
We have seen 380 institutional investors add shares of NBIX stock to their portfolio, and 280 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,338,472 shares (-76.4%) from their portfolio in Q4 2025, for an estimated $331,665,483
- PRICE T ROWE ASSOCIATES INC /MD/ removed 994,491 shares (-34.7%) from their portfolio in Q4 2025, for an estimated $141,048,658
- CITADEL ADVISORS LLC removed 713,528 shares (-90.0%) from their portfolio in Q4 2025, for an estimated $101,199,676
- TWO SIGMA ADVISERS, LP added 693,819 shares (+466.4%) to their portfolio in Q4 2025, for an estimated $98,404,348
- TWO SIGMA INVESTMENTS, LP added 637,246 shares (+183.3%) to their portfolio in Q4 2025, for an estimated $90,380,600
- UBS GROUP AG added 618,956 shares (+169.8%) to their portfolio in Q4 2025, for an estimated $87,786,529
- MORGAN STANLEY removed 617,559 shares (-33.8%) from their portfolio in Q4 2025, for an estimated $87,588,392
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NBIX Analyst Ratings
Wall Street analysts have issued reports on $NBIX in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/12/2026
- Needham issued a "Buy" rating on 02/12/2026
- Truist Securities issued a "Buy" rating on 01/08/2026
- Stifel issued a "Buy" rating on 12/11/2025
- TD Cowen issued a "Buy" rating on 12/05/2025
- Piper Sandler issued a "Overweight" rating on 10/29/2025
- RBC Capital issued a "Outperform" rating on 10/29/2025
To track analyst ratings and price targets for NBIX, check out Quiver Quantitative's $NBIX forecast page.
NBIX Price Targets
Multiple analysts have issued price targets for $NBIX recently. We have seen 17 analysts offer price targets for $NBIX in the last 6 months, with a median target of $178.0.
Here are some recent targets:
- Jeffrey Hung from Morgan Stanley set a target price of $185.0 on 04/10/2026
- Laura Chico from Wedbush set a target price of $166.0 on 04/07/2026
- Sumant Kulkarni from Canaccord Genuity set a target price of $200.0 on 04/07/2026
- Yigal Nochomovitz from Citigroup set a target price of $242.0 on 04/07/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $215.0 on 04/07/2026
- Ami Fadia from Needham set a target price of $185.0 on 04/06/2026
- Anupam Rama from JP Morgan set a target price of $177.0 on 03/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
